Pharmaceutical

Gilead acquires CymaBay Therapeutics for $4.3bn

Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.

Mar 26, 2024 - 00:00
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.
Read the original article

Tags:

Previous Article

Birmingham University to develop lollipop for mouth cancer detection

Next Article

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Boston Scientific cancels $230 million deal to buy Korean device company

STAT+: Boston Scientific cancels $230 million deal to b...

May 25, 2023

Texas wants to wean trans youth off meds in a ‘safe and medically appropriate’ way. Doctors say that’s impossible

Texas wants to wean trans youth off meds in a ‘safe and...

May 27, 2023

US FDA approves Novartis’ Fabhalta in IgAN treatment

US FDA approves Novartis’ Fabhalta in IgAN treatment

Aug 9, 2024